comparemela.com

Latest Breaking News On - Paul matteis - Page 11 : comparemela.com

Biogen s CEO Didn t Mention an Impending FDA Decision, Sending the Stock Down

Despite generally positive earnings and a cost-savings plan that will reduce the company’s head count by 1,000, shares of Biogen have traded down sharply.

Josh nathan kazisStifel paul matteisJefferie michael yeeAdam glanzman bloombergChristopher viehbacherDrug administrationSage therapeuticsMichael yeePaul matteisArticle normalBiotechnology servicesAnti depressantsHealthcare life sciencesSpecialized drugs medicationsRegulation government policyNew products services

Biogen (BIIB) Q2 2023 Earnings Call Transcript

BIIB earnings call for the period ending June 30, 2023.

South koreaUnited kingdomUnited statesGreat britainRobyn karnauskasChris viehbacherSalveen richter goldman sachsRobyn karnauskas truistSusan langerChristopher viehbacherPriya singhalBrian skorneySalveen richterChris schott jpmorganLynn kramerEvan seigerman

Roche buys into Alnylam heart drug in cardiovascular research bet

BioPharma

Yvonne greenstreetPaul matteisBristol myers squibbMerck coAlnylam pharmaceuticalsMedicines company

FDA s OK Isn t Always a Happy Day for Biotech Investors | Mint #AskBetterQuestions

Recent approvals of drugs, such as Biogen’s Leqembi, have left investors unimpressed

David wainerPaul matteisEisai leqembiReata pharmaceuticalsDrug administrationBiomarin pharmaceuticalSarepta therapeutic elevidysUs fda

Alzheimer s drug Leqembi sales may be slow at first: Analysts

Analysts believe the Medicare registry requirement and new guidance on Leqembi's prescription label could potentially weigh on sales in the near term.

Michael yeeMarc goodmanYatin sunejaPaul matteisJefferie yeeNational institute onDrug administrationNational instituteBiotech and pharmaceuticalsHealth care industryEisai co ltdBiogen incSocial issuesAlzheimer x27s diseaseBusiness news

vimarsana © 2020. All Rights Reserved.